14 studies found for:    " April 04, 2012":" May 04, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" April 04, 2012":" May 04, 2012"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Terminated The Mochudi Prevention Project ART Protocol
Condition: HIV Infections
Intervention: Drug: highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine
2 Completed A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: Maraviroc;   Drug: Combivir;   Drug: GSK2838510
3 Recruiting Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer
Conditions: Cervical Cancer;   Acquired Immunodeficiency Syndrome
Interventions: Drug: cisplatin;   Radiation: external beam radiation therapy
4 Completed A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 Oral;   Drug: GSK1265744 LAP 800mg intramuscular injection;   Drug: GSK1265744 LAP 200mg subcutaneous injection;   Drug: GSK1265744 LAP 200mg intramuscular injection;   Drug: GSK1265744 LAP 400mg intramuscular injection;   Drug: TMC278 LA 1200mg intramuscular injection;   Drug: TMC278 LA 600mg intramuscular injection
5 Active, not recruiting Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-MAG vaccine;   Biological: IL-12 pDNA adjuvant;   Biological: VSV HIV gag vaccine;   Biological: Placebo;   Device: Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
6 Active, not recruiting Cell Phone Messaging to Improve Communication of Critical Laboratory Results to Patients in Rural Uganda
Conditions: HIV;   Tuberculosis
Intervention: Other: Cellular Phone Text Message Formats
7 Active, not recruiting Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)
Conditions: HIV;   Osteoporosis
Intervention:
8 Recruiting Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily
Condition: HIV
Intervention: Drug: Lopinavir/ritonavir 800 mg / 200mg
9 Recruiting Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
Condition: HIV
Intervention: Drug: Tesamorelin for injection
10 Completed Enhancing HIV Risk Reduction Among Indian Women With Risky Husbands
Condition: Behavioral Risk for HIV
Intervention: Behavioral: RHANI WIves
11 Completed Experimental Analysis of HIV Risk Assessment Reactivity in South African Clinics
Condition: HIV Prevention and Assessment Reactivity
Interventions: Behavioral: Detailed baseline interview, enhanced HIV intervention;   Behavioral: General baseline interview, enhanced HIV intervention;   Behavioral: No baseline interview, enhanced HIV intervention;   Behavioral: Detailed baseline interview, standard of care intervention;   Behavioral: General baseline interview, standard of care intervention;   Behavioral: No baseline interview, standard of care intervention
12 Active, not recruiting Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Conditions: Diabetic Retinopathy;   HIV
Interventions: Drug: Tesamorelin;   Drug: Placebo-Control
13 Recruiting The Health Access and Recovery Peer Program
Conditions: Hypertension;   Arthritis;   Coronary Artery Disease;   Hepatitis;   Diabetes;   Asthma;   Hyperlipidemia;   HIV
Intervention: Behavioral: HARP Intervention
14 Active, not recruiting Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress
Condition: Cardiovascular Disease
Interventions: Drug: Efavirenz;   Drug: Rilpivirine

Indicates status has not been verified in more than two years